Published in Cancer Weekly, February 24th, 2004
Research and development expenses for the three months ended December 31, 2003, were $6.2 million, compared to $5.8 million during the same period of the prior fiscal year.
While total research and development expenses increased $0.4 million, total personnel costs declined approximately $0.4 million, primarily due to reduced headcount.
These savings were...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.